Epistatus® 10mg oromucosal solution Midazolam now available to prescribe

Posted in Industry News,News Review on 8th Jan 2018

 

Source: Veriton Pharma
Published online: 8/1/18


Veriton Pharma Ltd (formerly Special Products Ltd) has announced that Epistatus® 10mg Oromucosal Solution, Midazolam, is now available to prescribe. The NHS price for a single 10mg in 1mL pre-filled syringe is £45.76.

Epistatus® is licensed for use
 in the treatment of prolonged,
 acute convulsive seizures in
 children and adolescents aged 
10 to less than 18 years, who 
have been diagnosed with 
epilepsy1. Buccal midazolam is recommended by NICE2 for the management of prolonged acute convulsive seizures, and is preferred by most patients and carers compared to the administration of rectal diazepam3,4.

Epistatus is presented “ready-to-use”
in a novel, pre-filled, single-dose syringe, to provide carers with the confidence that they are administering the correct dose1,5. The pre-filled syringe is contained within a specially-designed, secure and tamper-evident protective packaging.

Dr Rohit Shankar FRCPsych, Consultant in Adult Developmental Neuropsychiatry – CFT and Hon. Associate Clinical Professor – Exeter Medical School commented:

The importance of having an alternate licensed preparation for use in the treatment of prolonged, acute convulsive seizures, especially in a different mode of delivery is an asset to both clinicians and patients.

In response to market research and insights, Veriton Pharma has invested heavily in the development of this new bespoke syringe, which is designed to allow simple administration of the dose into the buccal cavity5.

For further information on
 Epistatus 10mg oromucosal midazolam pre-filled syringes, please visit www.epistatus.co.uk

References:

  1. 
Epistatus 10mg oromucosal solution. Summary of Product Characteristics.
  1. National Institute for Health and Care Excellence (2012). The epilepsies: the diagnosis and management of epilepsies in adults and children in primary care. NICE clinical guideline CG 137.
  2. Nakken K and Lossius M. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand: (2011); 124:99-103.
  3. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. European Journal of Paediatric Neurology (2010); doi10.1016/j.ejpn.2010.05.009.
  4. Data on le – Excerpts from Epistatus Patent Application.
SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.